Highly active antiretroviral therapy and viral response in HIV type 2 infection

Clinical Infectious Diseases

Volumn 38, Issue 12, 2004, Pages 1771-1779

  Mullins, Christopher ^a   Eisen, Geoffrey ^a   Popper, Stephen ^f   Sarr, Abdoulaye Dieng ^a   Sankalé, Jean Louis ^a   Berger, Judith J ^g   Wright, Sharon B ^b   Chang, Hernan R ^c   Coste, Gérard ^e   Cooley, Timothy P ^c,d   Rice, Peter ^c   Skolnik, Paul R ^c   Sullivan, Margaret ^c   Kanki, Phyllis J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CAMBRIDGE HOSPITAL   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ST BARNABAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; UNITED STATES; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-2; HUMANS; MALE; MIDDLE AGED; UNITED STATES; VIRAL LOAD;

EID: 2942643918     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421390     Document Type: Article

References (37)

1. Barin F, M'Boup S, Denis F, et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa. Lancet 1985; 2:1387-9.
2. Clavel F. Isolation of a new human retrovirus from west African patients with AIDS. Science 1986; 233:343-6.
3. Kanki PJ. New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). Science 1986; 232:238-43.
4. Kanki PJ, DeCock K. Epidemiology and natural history of HIV-2. AIDS 1994; 8:S85-93.
5. Smallman-Raynor M, Cliff A. The spread of human immunodeficiency virus type 2 into Europe: a geographical analysis. Int J Epidemiol 1991; 20:480-9.
6. Horsburgh CR Jr, Holmberg SD. The global distribution of human immunodeficiency virus type 2 (HIV-2) infection. Transfusion 1988; 28:192-5.
7. Kanki PJ, Travers KU, MBoupS, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943-6.
8. Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272:462-6.
9. Morgan G, Wilkins HA, Pepin J, Jobe O, Brewster D, Whittle H. AIDS following mother-to-child transmission of HIV-2. AIDS 1990; 4:879-82.
10. Matheron S, Courpotin C, Simon F, et al. Vertical transmission of HIV-2. Lancet 1990; 335:1103-4.
11. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-90.
12. Kanki PJ. Human immunodeficiency virus type 2 (HIV-2). AIDS Rev 1999; 1:101-8.
13. Acquired immunodeficiency syndrome (AIDS). Proposed WHO criteria for interpreting results from Western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-II. Wkly Epidemiol Rec 1990; 65:281-3.
14. Gueye-Ndiaye A. Cost-effective diagnosis of HIV-1 and HIV-2 by recombinant-expressed envpeptide (566/996) dot-blot analysis. AIDS 1993; 7:475-81.
15. Grankvist O, Bredberg-Raden U, Gustafsson A, et al. Improved detection of HIV-2 DNA in clinical samples using a nested primer-based polymerase chain reaction. J Acquir Immune Defic Syndr 1992; 5:286-93.
16. + lymphocyte counts. AIDS 1998; 12:131-7.
17. Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116-21.
18. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-19.
19. Popper SJ, Sankale JL, Thior I, et al. Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression. AIDS Res Hum Retroviruses 1998; 14:1157-62.
20. Mirochnick M, Dorenbaum A, Blanchard S, et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr 2003; 33:153-6.
21. Ayanian JZ. HIV-2 infection in the United States. N Engl J Med 1989; 320:1422-3.
22. Clark NM. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy. AIDS 1998; 12:2506-7.
23. van der Ende ME. HIV-2 infection in 12 European residents: virus characteristics and disease progression. AIDS 1996; 10:1649-55.
24. van der Ende ME. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2000; 25:11-8.
25. Debyser Z. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci USA 1991; 88:1451-5.
26. Witvrouw M. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. Antivir Chem Chemother 1999; 10:211-7.
27. Cox SW. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res Hum Retroviruses 1994; 10:1725-9.
28. Mitsuya H. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human - lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82:7096-100.
29. Mitsuya H. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986; 83:1911-5.
30. Mitsuya H. Strategies for antiviral therapy in AIDS. Nature 1987; 325:773-8.
31. Mitsuya H. Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2′,3′-dideoxynucleosides in vitro. AIDS Res Hum Retroviruses 1988; 4:107-13.
32. Perach M. Resistance to nucleoside analogs of selective mutants of human immunodeficiency virus type 2 reverse transcriptase. J Virol 1995; 69:509-12.
33. Perach M. Analysis of HIV-2 RT mutants provides evidence that resistance of HIV-1 RT and HIV-2 RT to nucleoside analogs involves a repositioning of the template-primer. J Mol Biol 1997; 268:648-54.
34. Pichova I. Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study. Arch Biochem Biophys 1997; 341:62-9.
35. Kiso Y. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Biopolymers 1996; 40:235-44.
36. Weber J, Majer P, Litera J, et al. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds. Arch Biochem Biophys 1997; 341:62-9.
37. + cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003; 17:S49-54.